Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05485428
Other study ID # UPlymouthCH
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2023
Est. completion date May 1, 2024

Study information

Verified date May 2024
Source University of Plymouth
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project aims to investigate the practicality and utility of home-based high-intensity interval training (HIIT) by undertaking a previously developed, novel home-based HIIT intervention for people with Parkinson's (PwP).


Description:

This is a randomised controlled feasibility study with mechanistic, physiological and clinical sub components. Participants will be undertaking a 12-week home-based high-intensity interval training intervention. The programme is a feasibility study, previously co-created by people with Parkinson's and clinicians within an iterative planning process of focus groups and exercise testing. Following recruitment, participants will undertake initial baseline assessments. These will involve collection of anthropometric measurements and general lifestyle and Parkinson's related information, followed by pre-intervention mechanistic, physiological and clinical outcome measures. Participants will then be randomised to the HIIT intervention, or usual care control group. Both groups will then undertake 7 days pre-intervention physical activity monitoring following accelerometer instruction, as a baseline measure of habitual physical activity (an important confounding variable). Following an initial home visit, participants will then undertake a 12-week high-intensity interval training programme in the home setting, with supplied exercise equipment including music and exercise prompts, and remote support and online resources. Participants will complete a 32 minute training session 3 times per week, with at least one day of rest between sessions. Participants will be loaned heart rate monitoring devices, which will remotely record heart rate per exercise session. During week 7 of the intervention, participants will be asked to repeat 7 days of accelerometer wearing to compare habitual physical activity. Participants will record feasibility and safety aspects such as HIIT participation / adverse effects and events / exercise adaptations in diaries during the course of the intervention. Participants will then undergo post-intervention outcome measures. Participants will also be asked to be involved in a 45-minute post intervention focus group as part of a process evaluation. Depending on numbers, it is likely that there will be 2 of these parallel groups.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date May 1, 2024
Est. primary completion date April 25, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Diagnosed with Parkinson's disease - Aged 18 years or older (No upper limit) - Hoehn and Yahr stages 1-3 (Mild to moderate disease severity) - Capacity to consent under the Mental Capacity Act 2005, and able to follow an exercise programme - Based at home with enough space to perform an exercise programme - Willing and able to travel to intervention assessments - Access to a computer, Smart Phone, or tablet and to the internet. Exclusion criteria: - Other concurrent neurological condition - Co-morbidities that would prevent / be exacerbated by high-intensity exercise such as forms of cardiovascular disease - Advised to not participate following medical consultation - Participation in a contemporaneous interventional study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
High-intensity interval training
12-weeks of high intensity interval exercise, 30 minutes thrice weekly

Locations

Country Name City State
United Kingdom University Hospitals Plymouth NHS Trust Plymouth Devon

Sponsors (1)

Lead Sponsor Collaborator
University of Plymouth

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Total weekly habitual physical activity Weekly physical activity (minutes) measured with accelerometer, self administered 1 week prior to start of exercise programme after baseline assessments
Other Total weekly habitual physical activity Weekly physical activity (minutes) measured with accelerometer, self administered During week 7 of the exercise programme
Other Maximum heart rate Beats per minute, to be measured during VO2max assessment 1 week before first exercise session
Other Height Height (centimetres) with stadiometer 1 week before first exercise session
Other Weight Weight (kilograms) with calibrated digital scales 1 week before first exercise session
Other Lifestyle data questionnaire 10-item basic lifestyle data bespoke questionnaire 1 week before first exercise session
Other Health screening questionnaire Screening for health issues that may prevent participation 1 week before first exercise session at baseline assessments
Primary Programme completion Number of weeks of exercise programme completed, self administered Through study completion, an average of 12 weeks
Primary Programme adherence Number of exercise sessions completed in full, self administered Through study completion, an average of 12 weeks
Primary Change from baseline brain derived neurotrophic factor (BDNF) Blood sample: Brain-derived neurotrophic factor (pg/ml) 1 week before first exercise session and 1 day after last session.
Primary Change from baseline Relative VO2max Maximal oxygen uptake (ml/min/kg) incremental exercise test 1 week before first exercise session and 1 day after last session.
Secondary Adverse effects and events Adverse effects and events related to exercise sessions, self administered Through study completion, an average of 12 weeks
Secondary Change from baseline 30 second sit to stand test Number of times standing in 30 seconds 1 week before first exercise session and 1 day after last session.
Secondary Oxford Participation Activities Questionnaire Participant administered lifestyle questionnaire 1 week before first exercise session and 1 day after last session
Secondary Change from baseline Movement Disorder Society Unified Parkinson's Disease Rating Scale part 3 Motor examination, minimum score 0, maximum score 76, higher scores indicate increased disease severity 1 week before first exercise session and 1 day after last session.
Secondary Exercise intensity Achieved exercise intensity (% of maximum heart rate), self administered Through study completion, an average of 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Completed NCT02927691 - Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial Phase 2
Terminated NCT02924194 - Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease N/A